Immunotherapy in Prostate Cancer

被引：8

作者：

Sobol, Ilya ^{[1
]}

Thompson, R. H. ^{[1
]}

Dong, Haidong ^{[1
]}

Krco, Christopher ^{[1
]}

Kwon, Eugene D. ^{[1
]}

机构：

[1] Mayo Clin, Rochester, MN 55902 USA

来源：

CURRENT UROLOGY REPORTS | 2015年 / 16卷 / 06期

关键词：

Prostate cancer; Immunotherapy; PSA-TRICOM; Ipilimumab; SIPULEUCEL-T; DOUBLE-BLIND; PLACEBO; TRIAL; ACTIVATION; ANTIGEN; LIGAND;

D O I：

10.1007/s11934-015-0509-7

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

Immunotherapy for the treatment of malignant neoplasms has made significant progress over the last 20 years. Multiple molecular targets and clinical agents have been developed recently, particularly in the field of metastatic adenocarcinoma of the prostate. Sipuleucel-T is currently the only FDA approved immunotherapy for prostate cancer. PSA-TRICOM (Prostvac) currently has a phase III randomized trial underway after a phase II trial showed an improvement in overall survival. Interestingly, both these agents showed improvement in overall survival with no measurable change in disease state, leading to significant controversy as the utility of these agents in prostate cancer. Ipilimumab revealed a benefit for a sub-cohort of men in a post-docetaxel group and is currently undergoing investigation in a pre-docetaxel group. There are a number of other targets such as PD-1 which have shown effectiveness in other neoplasms that will likely be investigated in the future for use in prostate cancer.

引用

页码：1 / 5

页数：5

共 50 条

[11] Immunotherapy of prostate cancer
Freedland S.J.
Pantuck A.J.
Weider J.
Zisman A.
Belldegrun A.S.
Current Urology Reports, 2001, 2 (3) : 242 - 247
[12] Immunotherapy in Prostate Cancer
Fay, Emily K.
Graff, Julie N.
CANCERS, 2020, 12 (07) : 1 - 17
[13] Immunotherapy in prostate cancer
Lekili, Murat
UROONKOLOJI BULTENI-BULLETIN OF UROONCOLOGY, 2011, 10 (02): : 82 - 84
[14] Prostate cancer immunotherapy
McNeel, Douglas G.
CURRENT OPINION IN UROLOGY, 2007, 17 (03) : 175 - 181
[15] Immunotherapy for Prostate Cancer
Venturini, Nicholas J.
Drake, Charles G.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE, 2019, 9 (05):
[16] Prostate Cancer Immunotherapy
May, Kenneth F., Jr.
Gulley, James L.
Drake, Charles G.
Dranoff, Glenn
Kantoff, Philip W.
CLINICAL CANCER RESEARCH, 2011, 17 (16) : 5233 - 5238
[17] Immunotherapy in Prostate Cancer
Ilya Sobol
R. H. Thompson
Haidong Dong
Christopher Krco
Eugene D. Kwon
Current Urology Reports, 2015, 16
[18] Immunotherapy for prostate cancer
Fong L.
Small E.J.
Current Urology Reports, 2006, 7 (3) : 239 - 246
[19] Immunotherapy in Prostate Cancer
Panesar, Kiran
US PHARMACIST, 2016, 41 (08) : HS2 - HS5
[20] The immunotherapy of prostate cancer
AG Dalgleish
MJA Perry
JD Eaton
D Hrouda
SM Todryk
RS Kirby
Prostate Cancer and Prostatic Diseases, 2000, 3 : 303 - 307

← 1 2 3 4 5 →